[1] |
SOLEIMANI A, SOLEIMANI Z. Presentation and outcome of congenital heart disease during COVID-19 pandemic:a review[J]. Curr Probl Cardiol, 2022, 47(1):100905. DOI: 10.1016/j.cpcardiol.2021.100905.
|
[2] |
YANG J, ZHENG Y, GOU X,et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2:a systematic review and meta-analysis[J]. Int J Infect Dis, 2020, 94:91-95. DOI: 10.1016/j.ijid.2020.03.017.
|
[3] |
WANG X X, ZHANG H H, DU H,et al. Risk factors for COVID-19 in patients with hypertension[J]. Can J Infect Dis Med Microbiol, 2021, 2021:1-9. DOI: 10.1155/2021/5515941.
|
[4] |
HOFFMANN M, KLEINE-WEBER H, SCHROEDER S,et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052.
|
[5] |
MEZA N, PÉREZ-BRACCHIGLIONE J, PÉREZ I,et al. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19:a living systematic review of randomized clinical trials[J]. Medwave, 2021, 21(2):e8105. DOI: 10.5867/medwave.2021.02.8105.
|
[6] |
XU J, HUANG C, FAN G,et al. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak:a retrospective analysis[J]. Front Med, 2020, 14(5):601-612. DOI: 10.1007/s11684-020-0800-y.
|
[7] |
MENG J, XIAO G H, ZHANG J J,et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension[J]. Emerg Microbes Infect, 2020, 9(1):757-760. DOI: 10.1080/22221751.2020.1746200.
|
[8] |
ZHOU X, ZHU J K, XU T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors[J]. Clin Exp Hypertens, 2020, 42(7):656-660. DOI: 10.1080/10641963.2020.1764018.
|
[9] |
LI J Y, WANG X F, CHEN J,et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan,China[J]. JAMA Cardiol, 2020, 5(7):825-830. DOI: 10.1001/jamacardio.2020.1624.
|
[10] |
HU J H, ZHANG X L, ZHANG X,et al. COVID-19 patients with hypertension have more severity condition,and ACEI/ARB treatment have no influence on the clinical severity and outcome[J]. J Infect, 2020, 81(6):979-997. DOI: 10.1016/j.jinf.2020.05.056.
|
[11] |
ZHANG P, ZHU L H, CAI J J,et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ receptor blockers with mortality among patients with hypertension hospitalized with COVID-19[J]. Circ Res, 2020, 126(12):1671-1681. DOI: 10.1161/CIRCRESAHA.120.317134.
|
[12] |
SENKAL N, MERAL R, MEDETALIBEYOGLU A,et al. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19[J]. Anatol J Cardiol, 2020, 24(1):21-29. DOI: 10.14744/AnatolJCardiol.2020.57431.
|
[13] |
SARDU C, MAGGI P, MESSINA V,et al. Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy[J]. J Am Heart Assoc, 2020, 9(17):e016948. DOI: 10.1161/JAHA.120.016948.
|
[14] |
YANG G, TAN Z H, ZHOU L,et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection,inflammatory status,and clinical outcomes in patients with COVID-19 and hypertension:a single-center retrospective study[J]. Hypertension, 2020, 76(1):51-58. DOI: 10.1161/HYPERTENSIONAHA.120.15143.
|
[15] |
XIAO G H, HU H B, WU F,et al. Acute kidney injury in patients hospitalized with COVID-19 in Wuhan,China:a single-center retrospective observational study[J]. J South Med Univ, 2021, 41(2):157-163. DOI: 10.12122/j.issn.1673-4254.2021.02.01.
|
[16] |
LIU Y X, XU J, YANG P H,et al. Anti-hypertensive angiotensin Ⅱ receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients[J]. medRxiv, 2020. DOI: 10.1101/2020.03.20.20039586.
|
[17] |
GAO C, CAI Y, ZHANG K,et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality:a retrospective observational study[J]. Eur Heart J, 2020, 41(22):2058-2066. DOI: 10.1093/eurheartj/ehaa433.
|
[18] |
FELICE C, NARDIN C, DI TANNA G L,et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19:results from an Italian cohort of 133 hypertensives[J]. Am J Hypertens, 2020, 33(10):944-948. DOI: 10.1093/ajh/hpaa096.
|
[19] |
FENG Z C, LI J, YAO S H,et al. The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019:a multicenter data analysis[J]. medRxiv, 2020. DOI: 10.1101/2020.04.08.20057539.
|
[20] |
REYNOLDS H R, ADHIKARI S, PULGARIN C,et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19[J]. N Engl J Med, 2020, 382(25):2441-2448. DOI: 10.1056/NEJMoa2008975.
|
[21] |
HUANG Z Y, CAO J T, YAO Y M,et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension[J]. Ann Transl Med, 2020, 8(7):430. DOI: 10.21037/atm.2020.03.229.
|
[22] |
|
[23] |
GUAN W J, NI Z Y, HU Y,et al. China medical treatment expert group for,Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720. DOI: 10.1056/NEJMoa2002032.
|
[24] |
KREUTZ R, ALGHARABLY E A E, AZIZI M,et al. Hypertension,the renin-angiotensin system,and the risk of lower respiratory tract infections and lung injury:implications for COVID-19[J]. Cardiovasc Res, 2020, 116(10):1688-1699. DOI: 10.1093/cvr/cvaa097.
|
[25] |
KOCHI A N, TAGLIARI A P, FORLEO G B,et al. Cardiac and arrhythmic complications in patients with COVID-19[J]. J Cardiovasc Electrophysiol, 2020, 31(5):1003-1008. DOI: 10.1111/jce.14479.
|
[26] |
LI X C, ZHANG J F, ZHUO J L. The vasoprotective axes of the renin-angiotensin system:physiological relevance and therapeutic implications in cardiovascular,hypertensive and kidney diseases[J]. Pharmacol Res, 2017, 125(Pt A):21-38. DOI: 10.1016/j.phrs.2017.06.005.
|
[27] |
PRANATA R, PERMANA H, HUANG I,et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19):a systematic review and meta-analysis[J]. Diabetes Metab Syndr, 2020, 14(5):983-990. DOI: 10.1016/j.dsx.2020.06.047.
|
[28] |
SON M, SEO J, YANG S. Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in south Korea[J]. Hypertension, 2020, 76(3):742-749. DOI: 10.1161/HYPERTENSIONAHA.120.15464.
|
[29] |
CHEN N S, ZHOU M, DONG X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]. Lancet, 2020, 395(10223):507-513. DOI: 10.1016/S0140-6736(20)30211-7.
|